University of Patras
Σύγκριση της πρασουγρέλης σε σχέση με την διπλή δόση κλοπιδογρέλης σε ασθενείς που έχουν υποβληθεί σε αγγειοπλαστική και παρουσιάζουν αντίσταση στη συνήθη δόση κλοπιδογρέλης, όπως αυτή προσδιορίζεται με την χρήση του μετρητή VerifyNow
Abstract
dc:descriptionOBJECTIVES:The primary aim of the study was to determine the antiplatelet effects of prasugrel versus high-dose clopidogrel in patients with high on-treatment platelet reactivity (HTPR) after percutaneous coronary intervention (PCI) and, secondarily, their relation to cytochrome (CYP) 2C19*2 carriage.BACKGROUND:High on-treatment platelet reactivity after clopidogrel administration after PCI is linked to the loss-of-function CYP2C19*2 allele and accompanied by an increased risk of adverse events.METHODS:We performed a prospective, randomized, single-blind, crossover study of platelet inhibition by prasugrel 10 mg/day versus high-dose 150 mg/day clopidogrel in 71 (of 210 screened; 33.8%) post-PCI patients with HTPR. Platelet function was assessed by the VerifyNow assay (Accumetrics, San Diego, California), and real-time polymerase chain reaction genotyping was performed for CYP2C19*2 carriage.RESULTS:The primary endpoint of platelet reactivity (measured in platelet reactivity units) at the end of the 2 treatment periods was lower after prasugrel compared with clopidogrel (least-squares estimates 129.4, 95% confidence interval [CI]: 111.1 to 147.7 versus 201.7, 95% CI: 183.2 to 220.2; p < 0.001). The least-squares mean difference between the 2 treatments was -122.9 (95% CI: -166.7 to -79.2, p < 0.001), and -47.5 (95% CI: -79.5 to -15.4, p = 0.004), in carriers and noncarriers of at least 1 mutant allele, respectively. The HTPR rates were lower for prasugrel than for clopidogrel, in all patients (7.5% vs. 35.8%, p < 0.001), in carriers (5.3% vs. 47.4%, p = 0.007), and in noncarriers (8.8% vs. 29.4%, p = 0.005), respectively.CONCLUSIONS:In patients with HTPR after PCI, prasugrel is more effective compared with high clopidogrel in reducing platelet reactivity, particularly in CYP2C19*2 carriers. Genotyping guidance might be helpful only in case an increased clopidogrel maintenance dose is considered.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Dimitropoulos, Gerasimos
- Δημητρόπουλος, Γεράσιμος
Subjects
dc:subject × 20- Κλοπιδογρέλη
- Πρασουγρέλη
- Αντιαιμοπεταλιακά φάρμακα
- Αντιδραστικότητα αιμοπεταλίων
- Αιμοπεταλιακή λειτουργία
- Συσκευή μέτρησης αντίστασης
- Οξύ έμφραγμα μυοκαρδίου
- Αγγειοπλαστική στεφανιαίων αγγείων
- Clopidogrel
- Prasugrel
- Αntiplatelets
- Platelet reactivity
- Platelet function
- VerifyNow assay
- Percutaneous coronary intervention
- Acute myocardial infarction
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
dc:rights- Statement dc:rights
-
- BY_NC_ND
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45423